Breast cancer remains one of the most prevalent malignancies worldwide, with HER2-positive advanced breast cancer representing a particularly aggressive subtype. Clinical trials provide valuable efficacy data, but they often overlook the complexities of real-world patient journeys—including comorbidities, treatment changes, and long-term outcomes across diverse care settings.
Research challenge
Knowing whether a patient is HER2+, HER2-low, or HER2 IHC0 is no longer just an academic detail—it is a gateway to tailored, potentially life-extending therapy. The shift from a simple positive/negative classification to a more granular approach could ensure that many more patients receive the most effective treatments available now and in the future. For HER2-positive advanced breast cancer, understanding how targeted therapies are used in routine practice—and their impact on survival—requires a comprehensive, linked data approach.
Read the full case study
"*" indicates required fields
